Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

by Ysios Capital

3 years ago
lorundrostat, hypertension, Mineralys Therapeutics

Mineralys Therapeutics today presented data from the Target-HTN Phase 2 trial that further defines an endotype-specific targeted approach for treating uncontrolled or resistant hypertension with lorun...

Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, closes a €57 million in Series A financing led by Forbion, with participation from Ysios Capital and Sunstone Life Science Ventures

by Ysios Capital

3 years ago
Ysios Capital, Kynexis, KYN5356, brain diseases, KAT-II

This capital increase will allow Kynexis to advance the development of KYN5356, an innovative quinurenine aminotransferase II (KAT-II) enzyme inhibitor, for the treatment of cognitive impairment assoc...

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

by Ysios Capital

3 years ago
Mineralys Therapeutics, Target-HTN

Endotype identification from Target-HTN may represent a shift towards targeted, precision-directed therapy for hypertension management in future treatment paradigm

SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease

by Ysios Capital

3 years ago
SpliceBio, Spark Therapeutics, gene therapy LUXTURNA®, undisclosed inherited retinal disease, Protein Splicing

SpliceBio is pleased to announce the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a g...

AM-Pharma announces positive clinical data from phase 1b study evaluating ilofotase alfa in hypophosphatasia

by Ysios Capital

3 years ago
hypophosphatasia (HPP), Ilofotase alfa, AM-Pharma B.V.

AM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacemen...

Palex and Inbiomotion introduce pioneering test to aid oncologists in predicting recurrence and survival rates in breast cancer patients

by Ysios Capital

3 years ago
MAF gene, Palex Medical, Inbiomotion, MAF-TEST®, bisphosphonates

The MAF-TEST® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosp...

SparingVision Selects Second Target in Strategic Collaboration with Intellia Therapeutics

by Ysios Capital

3 years ago
SparingVision, CRISPR, Intellia

SparingVision today announces that it has selected a second target as part of its strategic collaboration with Intellia Therapeutics, Inc.to develop novel genomic medicines utilizing CRISPR-based gene...

Am-Pharma announces updated clinical development strategy

by Ysios Capital

3 years ago
ilofotase alfa, AM-Pharma, hypophosphatasia

Advancing ilofotase alfa into a Phase 2 study for lead indication cardiac surgery-associated renal damage

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

by Ysios Capital

3 years ago
lorundrostat, chronic kidney disease (CKD), Aldosterone, Mineralys Therapeutics

Mineralys Therapeutics today announced details of an expanded two-part Phase 2 clinical trial for lorundrostat as a potential therapy to treat patients with Stage 2 to 4 chronic kidney disease (CKD), ...

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics

by Ysios Capital

3 years ago
SparingVision, GIRK technology

SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for eye diseases, today announced that it has sold its ex vivo GIRK technology to Tenpoint Therapeutics.

Tagworks Pharmaceuticals Announces $65 Million in Series A Financing led by Ysios Capital and Gilde Healthcare, to Advance Click-to-Release Therapeutics

by Ysios Capital

3 years ago
TGW101, Tagworks Pharmaceuticals, Ysios Capital, cancer cell

Tagworks Pharmaceuticals BV (“Tagworks”), the pioneer of Click-to-Release chemistry designed to deliver more effective and safer systemic therapies, today announced a $65 million Series A financin...

CorWave Announces Second Closing of Its Series C Funding at €61M To Finance Its First Industrial Deployment

by Ysios Capital

3 years ago
CorWave

CorWave raised 61 million euros to fund its first industrial deployment and entry into clinical trials. SPI fund, managed by Bpifrance on behalf of the French Government as part of France 2030, and le...